Summit proceedings: Biomedical countermeasure development for emerging vector-borne viral diseases

Marcia A. Blackman; Mark A. Marchionni; John Gilly; Matthew Hepburn; Bruce L. Innis; Alan D.T. Barrett; Kent E. Kester; John R. Mascola; James F. Cummings; Thomas P. Monath; M. Cristina Cassetti; Jerome H. Kim; Melanie Saville; Stephen J. Thomas

doi:10.1016/j.vaccine.2019.08.061

Summit proceedings: Biomedical countermeasure development for emerging vector-borne viral diseases

Marcia A. Blackman, Mark A. Marchionni, John Gilly, Matthew Hepburn, Bruce L. Innis, Alan D.T. Barrett, Kent E. Kester, John R. Mascola, James F. Cummings, Thomas P. Monath, M. Cristina Cassetti, Jerome H. Kim, Melanie Saville, Stephen J. Thomas

Pathology

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Emerging and re-emerging infectious diseases are an expanding global threat to public health, security, and economies. Increasing populations, urbanization, deforestation, climate change, anti-vaccination movements, war, and international travel are some of the contributing factors to this trend. The recent Ebola, MERS-CoV, and Zika outbreaks demonstrated we are insufficiently prepared to respond with proven safe and effective countermeasures (i.e., vaccines and therapeutics). The State University of New York Upstate Medical University and the Trudeau Institute convened a summit of key opinion and thought leaders in the life sciences and biomedical research and development enterprises to explore global biopreparedness challenges, take an inventory of existing capabilities and capacities related to preparation and response, assess current “gaps,” and prospect what could be done to improve our position. Herein we describe the summit proceedings, “Translational Immunology Supporting Biomedical Countermeasure Development for Emerging Vector-borne Viral Diseases,” held October 2–3, 2018, at the Trudeau Institute in Saranac Lake, NY.

Original language	English (US)
Pages (from-to)	6248-6254
Number of pages	7
Journal	Vaccine
Volume	37
Issue number	43
DOIs	https://doi.org/10.1016/j.vaccine.2019.08.061
State	Published - Oct 8 2019

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.vaccine.2019.08.061

Cite this

Blackman, M. A., Marchionni, M. A., Gilly, J., Hepburn, M., Innis, B. L., Barrett, A. D. T., Kester, K. E., Mascola, J. R., Cummings, J. F., Monath, T. P., Cassetti, M. C., Kim, J. H., Saville, M., & Thomas, S. J. (2019). Summit proceedings: Biomedical countermeasure development for emerging vector-borne viral diseases. Vaccine, 37(43), 6248-6254. https://doi.org/10.1016/j.vaccine.2019.08.061

@article{ac7f1c3759c1468b90006bd4f1f8f7f1,

title = "Summit proceedings: Biomedical countermeasure development for emerging vector-borne viral diseases",

abstract = "Emerging and re-emerging infectious diseases are an expanding global threat to public health, security, and economies. Increasing populations, urbanization, deforestation, climate change, anti-vaccination movements, war, and international travel are some of the contributing factors to this trend. The recent Ebola, MERS-CoV, and Zika outbreaks demonstrated we are insufficiently prepared to respond with proven safe and effective countermeasures (i.e., vaccines and therapeutics). The State University of New York Upstate Medical University and the Trudeau Institute convened a summit of key opinion and thought leaders in the life sciences and biomedical research and development enterprises to explore global biopreparedness challenges, take an inventory of existing capabilities and capacities related to preparation and response, assess current “gaps,” and prospect what could be done to improve our position. Herein we describe the summit proceedings, “Translational Immunology Supporting Biomedical Countermeasure Development for Emerging Vector-borne Viral Diseases,” held October 2–3, 2018, at the Trudeau Institute in Saranac Lake, NY.",

author = "Blackman, {Marcia A.} and Marchionni, {Mark A.} and John Gilly and Matthew Hepburn and Innis, {Bruce L.} and Barrett, {Alan D.T.} and Kester, {Kent E.} and Mascola, {John R.} and Cummings, {James F.} and Monath, {Thomas P.} and Cassetti, {M. Cristina} and Kim, {Jerome H.} and Melanie Saville and Thomas, {Stephen J.}",

note = "Publisher Copyright: {\textcopyright} 2019",

year = "2019",

month = oct,

day = "8",

doi = "10.1016/j.vaccine.2019.08.061",

language = "English (US)",

volume = "37",

pages = "6248--6254",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "43",

}

TY - JOUR

T1 - Summit proceedings

T2 - Biomedical countermeasure development for emerging vector-borne viral diseases

AU - Blackman, Marcia A.

AU - Marchionni, Mark A.

AU - Gilly, John

AU - Hepburn, Matthew

AU - Innis, Bruce L.

AU - Barrett, Alan D.T.

AU - Kester, Kent E.

AU - Mascola, John R.

AU - Cummings, James F.

AU - Monath, Thomas P.

AU - Cassetti, M. Cristina

AU - Kim, Jerome H.

AU - Saville, Melanie

AU - Thomas, Stephen J.

PY - 2019/10/8

Y1 - 2019/10/8

N2 - Emerging and re-emerging infectious diseases are an expanding global threat to public health, security, and economies. Increasing populations, urbanization, deforestation, climate change, anti-vaccination movements, war, and international travel are some of the contributing factors to this trend. The recent Ebola, MERS-CoV, and Zika outbreaks demonstrated we are insufficiently prepared to respond with proven safe and effective countermeasures (i.e., vaccines and therapeutics). The State University of New York Upstate Medical University and the Trudeau Institute convened a summit of key opinion and thought leaders in the life sciences and biomedical research and development enterprises to explore global biopreparedness challenges, take an inventory of existing capabilities and capacities related to preparation and response, assess current “gaps,” and prospect what could be done to improve our position. Herein we describe the summit proceedings, “Translational Immunology Supporting Biomedical Countermeasure Development for Emerging Vector-borne Viral Diseases,” held October 2–3, 2018, at the Trudeau Institute in Saranac Lake, NY.

AB - Emerging and re-emerging infectious diseases are an expanding global threat to public health, security, and economies. Increasing populations, urbanization, deforestation, climate change, anti-vaccination movements, war, and international travel are some of the contributing factors to this trend. The recent Ebola, MERS-CoV, and Zika outbreaks demonstrated we are insufficiently prepared to respond with proven safe and effective countermeasures (i.e., vaccines and therapeutics). The State University of New York Upstate Medical University and the Trudeau Institute convened a summit of key opinion and thought leaders in the life sciences and biomedical research and development enterprises to explore global biopreparedness challenges, take an inventory of existing capabilities and capacities related to preparation and response, assess current “gaps,” and prospect what could be done to improve our position. Herein we describe the summit proceedings, “Translational Immunology Supporting Biomedical Countermeasure Development for Emerging Vector-borne Viral Diseases,” held October 2–3, 2018, at the Trudeau Institute in Saranac Lake, NY.

UR - http://www.scopus.com/inward/record.url?scp=85071845032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071845032&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2019.08.061

DO - 10.1016/j.vaccine.2019.08.061

M3 - Article

C2 - 31500964

AN - SCOPUS:85071845032

SN - 0264-410X

VL - 37

SP - 6248

EP - 6254

JO - Vaccine

JF - Vaccine

IS - 43

ER -

Summit proceedings: Biomedical countermeasure development for emerging vector-borne viral diseases

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this